Breast cancer
Results
Phase 2
This trial was done to see if trastuzumab can lower the number of circulating tumour cells after other treatment for breast cancer. This means cancer cells that have broken away from the original cancer and gone into the bloodstream.
The women taking part had:
cancer with none or very few proteins (HER2 negative cancer)
already had surgery and chemotherapy
The trial was supported by Cancer Research UK. It was open for people to join between 2013 and 2016. The team published the results in 2018.
Recruitment start: 30 April 2013
Recruitment end: 17 October 2016
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Anthony Kong
European Organisation for Research and Treatment of Cancer (EORTC)
NIHR Clinical Research Network: Cancer
Roche
There is more information about this trial on the clinicaltrials.gov website (NCT01548677):
Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer (TREAT-CTC)
Last reviewed: 1 December 2023
CRUK internal database number: 12703